Singapore, Aug. 1 -- Hong Kong headquartered Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, has announced the launch of the Drug Discovery and Development (DDD) Benchmarks as a Service (BaaS).

It is a pioneering standardised evaluation framework anchored in carefully decontaminated real-world data and proprietary validated programs. for measuring how frontier AI and foundation models built on other architectures perform on real-world tasks across medicinal chemistry, chemical synthesis, disease biology, clinical development, and longevity research.

Insilico's BaaS is available to any organisation developing frontier AI for drug discovery or leveraging foundation models in their...